<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068107</url>
  </required_header>
  <id_info>
    <org_study_id>030286</org_study_id>
    <secondary_id>03-N-0286</secondary_id>
    <nct_id>NCT00068107</nct_id>
  </id_info>
  <brief_title>Dosing Study of Replagal in Patients With Fabry Disease</brief_title>
  <official_title>Study of Weekly Dosing Regimens of Replagal in Patients With Fabry Disease With Incomplete Clinical Response to Long-Term Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety and effectiveness of increasing Replagal infusions in
      certain patients with Fabry disease. Replagal is a genetically engineered form of
      Alpha-galactosidase A, an enzyme that normally breaks down a fatty substance called
      globotriaosylceramide (Gb3). In patients with Fabry disease, Alpha-galactosidase A does not
      function properly and, therefore, Gb3 builds up, causing problems with the kidneys, heart,
      nerves, and blood vessels.

      Patients with Fabry disease who are participating in NIH protocol 00-N-0185 or 02-N-0220 may
      be eligible for this study. This includes patients who are currently taking Replagal but
      whose kidney function continues to worsen, or patients who have certain test results that are
      much improved after Replagal infusion.

      Participants will receive Replagal infusions (0.2 mg/kg body weight) through a vein once a
      week (as opposed to the previous dosage of once every 2 weeks) for up to 2 years. The first
      infusion, and some others, are given at the NIH Clinical Center, but most are administered by
      the patient's local doctor. Vital signs are measured before, immediately after, and 1 hour
      after each infusion.

      Baseline evaluations are done on an inpatient basis at the NIH Clinical Center over a 1-week
      period before and after the first Replagal infusion and at 6-month intervals during the
      study. Tests include a check of vital signs (temperature, respiratory rate, pulse rate, and
      blood pressure); weight measurement; physical and neurological examinations; routine blood
      and urine tests; 24-hour urine collection; electrocardiogram; and review of treatment side
      effects. In addition, the following tests are done:

        -  Quantitative sensory testing: This is a non-invasive test to measure the ability to
           sense warm, cold and vibration in the hand and foot.

        -  QSART: This test measures the amount of sweat in a particular area of skin that did not
           sweat enough. A small amount of a medicine called acetylcholine is put on the skin and
           made to enter the skin using a very small electric current.

        -  Doppler skin blood flow: This test measures blood flow to the blood vessels of the skin.
           A machine takes pictures of blood flow in the skin of the forearm using a laser beam.
           Pictures are taken before and during application of medicines that cause blood vessels
           to dilate. Acetylcholine is used on one forearm and nitroprusside is used on the other.
           The medication is made to enter the skin using a small el...
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: The goal of this study is to determine whether higher frequency of dosing of
      enzyme replacement therapy (ERT) can either significantly slow the decline of renal function
      or continuously sustain the normalization of other objective functions in patients with Fabry
      disease who have been receiving intravenous infusions of Replagal (agalsidase alfa) at a dose
      of 0.2 mg/kg of body weight administered every 2 weeks.

      Study Population: Patients with Fabry disease who are currently on clinical research
      protocols 00-N-0185/TKT011 or 02-N-0220/TKT015 and who have demonstrated progressive decline
      in calculated glomerular filtration rate (GFR) of at least 5 ml/min/year on ERT or who
      consistently show transient improvement in objective functions (such as sweating) in the few
      days post-infusion.

      Design: This is an open label study comparing one dosing regimen with a previous less
      intensive dosing regimen. Patients will receive a dose of 0.2 mg/kg of body weight every
      week.

      Outcome Measures: The main outcome measure will be a change in the mean linear rate of
      decline of the estimated calculated GFR. The main hypothesis is that a more frequent
      administration of the previous dose of Replagal will significantly reduce the mean slope of
      the decline of the calculated glomerular filtration rate GFR compared with the currently
      observed slope on a dose of 0.2 mg/kg administered every 2 weeks. At the 2-year time point,
      the dose will be increased to 0.4 mg/kg only in the patients whose GFR continues to
      significantly decline. Secondary outcome measures will be globotriaosylceramide (Gb(3)) in
      plasma and urinary sediment, quantitative sudomotor axon reflex test, quantitative sensory
      testing. Study duration is 2 years with a possibility of additional one-year extensions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Relagal was administered every 2 weeks for 2-4 years pre-study, Relagal was administred weekly during the study (approx. 4.5-10 years)</time_frame>
    <description>The rate of decline in renal function, as measured by estimation of glomerular filtration rate at baseline when participants were receiving agalsidase alfa (Relagal) every 2 weeks and when participants were receiving weekly infusion of Relagal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Globotriaosylceramide (Gb(3)) in Plasma</measure>
    <time_frame>Baseline and last observation (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Globotriaosylceramide (Gb(3)) in Urine Sediment</measure>
    <time_frame>Baseline and last observation (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Change in Quantitative Sudomotor Axon Reflex Test</measure>
    <time_frame>Baseline and last observation (up to 10 years)</time_frame>
    <description>Quantitative sudomotor axon reflex test (QSART) is a measure of sweat function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Sensory Testing</measure>
    <time_frame>pre-study was 2-4 years, during study sensory testing measured for approx. 4.5-5 years</time_frame>
    <description>For quantitative sensory testing, the outcome variable (detection threshold score) was analyzed for all combinations of location (foot, hand, and thigh) and test (cold, vibration, and warm). Possible threshold scores may range from 1-25. Score values of &quot;&gt;25&quot; were set to 25. Higher scores indicate higher sensory detection threshold. Therefore, lower score is better. Time, measured in years, was centered at the date in which patients switched treatment regimen. All available measurements were used. A linear mixed model analysis was used to test for differences in the linear association between time and detection threshold score pre-and-post ERT regiment change while accounting for the correlation among observations from the same individual. Specifically, the model contained a subject specific random intercept with year as a fixed effect and knot at time of the treatment change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doppler Skin Blood Flow</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Relagal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants received Relagal administered weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Replagal</intervention_name>
    <description>enzyme replacement therapy</description>
    <arm_group_label>Relagal</arm_group_label>
    <other_name>agalsidase alfa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Patients with Fabry disease participating in 00-N-0185/TKT011 or 02-N-0220/TKT015 may be
        eligible. No other Fabry patients will be eligible.

        Patients losing GFR at a rate greater than 5 ml/min/year despite ERT with agalsidase alfa
        for greater than or equal to 2.5 years in 00-N-0185/TKT/003/006/011 Study or ERT over
        greater than or equal to 1.0 years in 02-N-0220/TKT/010/015 Study.

        Patients who at least twice demonstrated significant improvement or normalization of sweat
        function (by QSART or thermoregulatory sweat test) or reduction in serum creatinine by at
        least 10% but return to the pre-infusion state before the subsequent biweekly enzyme
        infusion.

        Patients who freely agree to participate in this study and understand the nature, risks and
        benefits of this study and give their written informed consent.

        EXCLUSION CRITERIA:

        Patients with Fabry disease, who are not already part of 00-N-0185/TKT011 or
        02-N-0220/TKT015.

        Patients on these protocols who have stable serum creatinine (or a lesser rise in serum
        creatinine than stipulated in the inclusion criteria), and do not show other objective
        evidence of incomplete clinical response between biweekly infusions (e.g. sweat function).

        Patients who have begun dialysis or who have received a renal transplant.

        Patients who cannot tolerate the study procedures or who are unable or unwilling to travel
        to the study center as required by this protocol.

        Patients with an intercurrent medical condition that would render them unsuitable for mthe
        study e.g. HIV, diabetes. The reason is that the pathologies of these conditions will be
        significant confounders in assessing the effect of the experimental therapy and its adverse
        events.

        Patients who in the opinion of the investigator (for whatever reason) are thought to be
        unsuitable for the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis. 2000 Aug;26(4):285-90.</citation>
    <PMID>11042029</PMID>
  </reference>
  <reference>
    <citation>Brady RO. Enzymatic abnormalities in diseases of sphingolipid metabolism. Clin Chem. 1967 Jul;13(7):565-77. Review.</citation>
    <PMID>5006481</PMID>
  </reference>
  <reference>
    <citation>Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA. 2000 Dec 6;284(21):2771-5. Erratum in: JAMA 2001 Jan 10;285(2):169.</citation>
    <PMID>11105184</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2003</study_first_submitted>
  <study_first_submitted_qc>September 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2003</study_first_posted>
  <results_first_submitted>March 12, 2015</results_first_submitted>
  <results_first_submitted_qc>March 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2015</results_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lysosomal Storage</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Stroke</keyword>
  <keyword>Hypohidrosis</keyword>
  <keyword>Peripheral Neuropathy</keyword>
  <keyword>Fabry Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>13 participants were recruited; 1 participant was excluded because of stable kidney function; 12 started treatment</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>All participants were followed on a prior protocol and found to have a mean slope on Replagal (agalsidase alfa) infused every 2 weeks of -0.66 +- 0.24 ml/min/month. Patients will receive a dose of 0.2 mg/kg of body weight every week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>end-stage renal disease</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants were followed on a prior protocol and found to have a mean slope on Replagal (agalsidase alfa) infused every 2 weeks of -0.66 +- 0.24 ml/min/month.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimated Glomerular Filtration Rate (eGFR)</title>
        <description>The rate of decline in renal function, as measured by estimation of glomerular filtration rate at baseline when participants were receiving agalsidase alfa (Relagal) every 2 weeks and when participants were receiving weekly infusion of Relagal.</description>
        <time_frame>Relagal was administered every 2 weeks for 2-4 years pre-study, Relagal was administred weekly during the study (approx. 4.5-10 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants were followed on a prior protocol and found to have a mean slope on Replagal (agalsidase alfa) infused every 2 weeks of -0.66 +- 0.24 ml/min/month.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR)</title>
          <description>The rate of decline in renal function, as measured by estimation of glomerular filtration rate at baseline when participants were receiving agalsidase alfa (Relagal) every 2 weeks and when participants were receiving weekly infusion of Relagal.</description>
          <units>ml/min/month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>eGFR on infusions every 2 wks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eGFR on infusions weekly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>eGFR measured pre-study was compared to eGFR during the study</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Average Delay in time to ESRD</param_type>
            <param_value>166</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.4</ci_lower_limit>
            <ci_upper_limit>323.8</ci_upper_limit>
            <estimate_desc>The average delay in end stage renal disease (ESRD) calculated from the eGFR values and represents the estimated difference in time to ESRD between Relagal administered every 2 weeks and Relagal administered weekly. Units = months</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Globotriaosylceramide (Gb(3)) in Plasma</title>
        <time_frame>Baseline and last observation (up to 10 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants at Baseline</title>
            <description>All participants were followed on a prior protocol and found to have a mean slope on Replagal (agalsidase alfa) infused every 2 weeks of -0.66 +- 0.24 ml/min/month.</description>
          </group>
          <group group_id="O2">
            <title>All Participants at Last Observation</title>
          </group>
        </group_list>
        <measure>
          <title>Globotriaosylceramide (Gb(3)) in Plasma</title>
          <units>nanomole/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>participant 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35"/>
                    <measurement group_id="O2" value="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62"/>
                    <measurement group_id="O2" value="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43"/>
                    <measurement group_id="O2" value="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17"/>
                    <measurement group_id="O2" value="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78"/>
                    <measurement group_id="O2" value="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32"/>
                    <measurement group_id="O2" value="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69"/>
                    <measurement group_id="O2" value="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25"/>
                    <measurement group_id="O2" value="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59"/>
                    <measurement group_id="O2" value="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.62"/>
                    <measurement group_id="O2" value="5.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.56"/>
                    <measurement group_id="O2" value="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Globotriaosylceramide (Gb(3)) in Urine Sediment</title>
        <time_frame>Baseline and last observation (up to 10 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants at Baseline</title>
            <description>All participants were followed on a prior protocol and found to have a mean slope on Replagal (agalsidase alfa) infused every 2 weeks of -0.66 +- 0.24 ml/min/month.</description>
          </group>
          <group group_id="O2">
            <title>All Participants at Last Observation</title>
          </group>
        </group_list>
        <measure>
          <title>Globotriaosylceramide (Gb(3)) in Urine Sediment</title>
          <units>nanomole/(gram of Creatinine)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>participant 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="1888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3026"/>
                    <measurement group_id="O2" value="652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3128"/>
                    <measurement group_id="O2" value="1682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1393"/>
                    <measurement group_id="O2" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1457"/>
                    <measurement group_id="O2" value="488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2342"/>
                    <measurement group_id="O2" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participant 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="624"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Change in Quantitative Sudomotor Axon Reflex Test</title>
        <description>Quantitative sudomotor axon reflex test (QSART) is a measure of sweat function</description>
        <time_frame>Baseline and last observation (up to 10 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants were followed on a prior protocol and found to have a mean slope on Replagal (agalsidase alfa) infused every 2 weeks of -0.66 +- 0.24 ml/min/month.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Change in Quantitative Sudomotor Axon Reflex Test</title>
          <description>Quantitative sudomotor axon reflex test (QSART) is a measure of sweat function</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitative Sensory Testing</title>
        <description>For quantitative sensory testing, the outcome variable (detection threshold score) was analyzed for all combinations of location (foot, hand, and thigh) and test (cold, vibration, and warm). Possible threshold scores may range from 1-25. Score values of “&gt;25” were set to 25. Higher scores indicate higher sensory detection threshold. Therefore, lower score is better. Time, measured in years, was centered at the date in which patients switched treatment regimen. All available measurements were used. A linear mixed model analysis was used to test for differences in the linear association between time and detection threshold score pre-and-post ERT regiment change while accounting for the correlation among observations from the same individual. Specifically, the model contained a subject specific random intercept with year as a fixed effect and knot at time of the treatment change.</description>
        <time_frame>pre-study was 2-4 years, during study sensory testing measured for approx. 4.5-5 years</time_frame>
        <population>Number of participants with a sufficient number of data points to estimate slope</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants were followed on a prior protocol and found to have a mean slope on Replagal (agalsidase alfa) infused every 2 weeks of -0.66 +- 0.24 ml/min/month. Patients will receive a dose of 0.2 mg/kg of body weight every week.</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Sensory Testing</title>
          <description>For quantitative sensory testing, the outcome variable (detection threshold score) was analyzed for all combinations of location (foot, hand, and thigh) and test (cold, vibration, and warm). Possible threshold scores may range from 1-25. Score values of “&gt;25” were set to 25. Higher scores indicate higher sensory detection threshold. Therefore, lower score is better. Time, measured in years, was centered at the date in which patients switched treatment regimen. All available measurements were used. A linear mixed model analysis was used to test for differences in the linear association between time and detection threshold score pre-and-post ERT regiment change while accounting for the correlation among observations from the same individual. Specifically, the model contained a subject specific random intercept with year as a fixed effect and knot at time of the treatment change.</description>
          <population>Number of participants with a sufficient number of data points to estimate slope</population>
          <units>units on a scale/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cold Sensory testing on Foot (pre-study)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2108" spread="0.1366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold Sensory on Foot (difference pre- to post-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3863" spread="0.2784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vibration Sensory testing on Foot (pre-study)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3353" spread="0.1004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vibration on Foot (difference pre- to post-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3912" spread="0.2041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warm Sensory testing on Foot (pre-study)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08536" spread="0.09264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warm on Foot (difference pre- to post-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4169" spread="0.1887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold Sensory testing on Hand (pre-study)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1026" spread="0.1413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold on Hand (difference pre- to post-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5141" spread="0.2874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vibration Sensory testing on Hand (pre-study)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2279" spread="0.07427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vibration on Hand (difference pre- to post-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1966" spread="0.1503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warm Sensory testing on Hand (pre-study)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2138" spread="0.1179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warm on Hand (difference pre- to post-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1781" spread="0.2401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold Sensory testing on Thigh (pre-study)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2502" spread="0.1437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold on Thigh (difference pre- to post-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2991" spread="0.2884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warm Sensory testing on Thigh (pre-study)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.549" spread="0.1124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warm on Thigh (difference pre- to post-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8255" spread="0.2258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Doppler Skin Blood Flow</title>
        <time_frame>10 years</time_frame>
        <population>Doppler skin blood flow was not collected in this study because it was judged to not be useful early in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants were followed on a prior protocol and found to have a mean slope on Replagal (agalsidase alfa) infused every 2 weeks of -0.66 +- 0.24 ml/min/month.</description>
          </group>
        </group_list>
        <measure>
          <title>Doppler Skin Blood Flow</title>
          <population>Doppler skin blood flow was not collected in this study because it was judged to not be useful early in the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All SAEs were adjudicated to be disease related and not related to the agalsidase alfa infusions.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>All participants were followed on a prior protocol and found to have a mean slope on Replagal (agalsidase alfa) infused every 2 weeks of -0.66 +- 0.24 ml/min/month.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>syncopal episode</sub_title>
                <description>occurred while straining when lifting weight in a gym</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>elective mitral valve annuloplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>increased intensity of angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>recurrent ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>aortic valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>dizziness, tachycardia and chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>clogged port-a-cath replacement and pacemaker adjustment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>placement of a pacemaker due to a bradycardic episode</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hepatitis C infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sharp chest pain and right leg pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>pain crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>acute occipital ischemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>catheter-induced peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>advanced renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>severe renal decline</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ferritin - decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ferritin - increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Iron - decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Potassium - elevated</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sodium - elevated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cardiac palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Heart Block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing Loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroid</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>TSH - elevated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision - hazy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholethisiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>GI symptoms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stool leakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired balance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dreams (abnormal)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Glucose - elevated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain - back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain - chest (no specific angina)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain - finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain - GI</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain - knee</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain - leg (spastic)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain - neck area</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain - pelvic area</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain - shoulder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PSA - elevated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Throat - dry</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Virus - post transplant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weight loss - unexpected</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold symptoms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Eosinophils - increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury - trauma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Orthopedic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer - skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Memory - decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mental status altered</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Restless Leg Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Speech - impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stroke - acute ischemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine worsened</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dialysis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Electrolytes - elevated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Kidney nodules/cysts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Microalbuminuria - worsened</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Proteinuria - increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Prostatic hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Transplant - kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urine - bloody s/p prostate biopsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blisters</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ecchymosis - varied</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of subjects. Single group with comparison to baseline data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Raphael Schiffmann</name_or_title>
      <organization>Baylor Research Institute</organization>
      <phone>214-820-4533</phone>
      <email>raphael.schiffmann@baylorhealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

